RISE CAB training package
>
Skip to content
An Initiative of AVAC
Search

Resource Library

The PrEPWatch Resource Database offers a wide range of material on the status of PrEP as an option for biomedical HIV prevention around the world. Search this database to find step-by-step guidance for rolling out PrEP, summaries of the research to date on safety, efficacy and implementation, tools to assist planning and roll out, country updates on PrEP policy and access, and lessons learned from those efforts.

Filter By
Multiple filters can be used at once

Showing results 41 - 50 of 76

Selected Filters:
23 December 2022

Costs and Cost-Effectiveness of Biomedical, Non-Surgical HIV Prevention Interventions: A systematic literature review

This article from PharmacoEconomics synthesizes findings on cost and cost-effectivness of different biomedical HIV prevention options and identifies remaining knowledge gaps to suggest future research priorities.

Financing & Costing, Research

External Link
22 December 2022

Long-acting HIV Pre-exposure Prophylaxis (PrEP) Approaches: Recent advances, emerging technologies, and development challenges

This review from Expert Opinion on Drug Delivery discusses the current state of the long acting PrEP field, recent advances, and emerging technologies, including ARV prodrug modifications and new drug delivery systems. Technological challenges, knowledge gaps, preclinical testing considerations, and future directions important in the context of clinical translation and implementation of long acting HIV…

Research

External Link
22 December 2022

HIV Prevention for the Next Decade: Appropriate, person-centred, prioritised, effective, combination prevention

In light of the development of new HIV prevention technologies, this article from PLOS Medicine proposes a new approach to HIV prevention, that emphasises appropriate, person-centred, prioritised, effective, combination HIV prevention within a framework that reduces existing barriers to services and acknowledges heterogeneity, autonomy, and choice.

Community/Advocacy, Monitoring & Evaluation, Research, Service Delivery

External Link
24 November 2022

Potential of Long-Acting Products to Transform the Treatment and Prevention of Human Immunodeficiency Virus (HIV) in Infants, Children, and Adolescents

This article from Clinical Infectious Diseases examines the potential of injectable PrEP for HIV prevention in infants, children, and adolescents.

Research, Service Delivery

External Link
24 November 2022

Barriers to Uptake of Long-Acting Antiretroviral Products for Treatment and Prevention of HIV in Low- and Middle-Income Countries

This article from Clinical Infectious Diseases examines potential barriers to scale-up of injectable PrEP in low and middle income countries.

Research, Service Delivery

External Link
22 November 2022

Long-acting Injectable Cabotegravir (CAB for PrEP) for HIV Prevention: Community perspectives

During this 90-minute webinar, speakers will discuss community acceptability of and preferences for different PrEP options, including CAB for PrEP, barriers to implementation of CAB for PrEP, and engagement with communities as CAB for PrEP projects are being planned. This webinar is presented by the Global PrEP Network, a WHO-led forum designed to facilitate global…

Community/Advocacy, Service Delivery

Event
22 November 2022

A Qualitative Exploration of New and Existing HIV PrEP Modalities Among Men Who Have Sex with Men in Philadelphia

This article from Open Forum Infectious Diseases explores the treatment characteristics that may influence the willingness and uptake of long-acting injectable PrEP as opposed to the daily pills among a racially diverse sample of gay and bisexual men who have sex with men in Philadelphia, Pennsylvania, USA.

Demand Creation/Marketing, Service Delivery

External Link
10 November 2022

Relative Cost-effectiveness of Long-acting Injectable Cabotegravir versus Oral Pre-exposure Prophylaxis in South Africa based on the HPTN 083 and HPTN 084 Trials: A modelled economic evaluation and threshold analysis

This article from The Lancet HIV estimates the incremental cost-effectiveness of long-acting injectable cabotegravir (CAB for PrEP) compared with tenofovir disoproxil fumarate and emtricitabine (TDF/FTC oral PrEP) in South Africa, using methods standard to government planning, and determines the threshold price at which CAB for PrEP is as cost-effective as TDF/FTC oral PrEP.

Financing & Costing, Research

External Link
14 October 2022

Long-acting injectable cabotegravir for HIV prevention: WHO guidelines, implementation considerations, and project examples

Recording During this 90-minute webinar, speakers will provide an overview of the new WHO guidelines on CAB for PrEP, discuss implementation issues specifically relating to HIV testing and drug resistance, and highlight examples of planned implementation projects in sub-Saharan Africa and Asia. This webinar is presented by the Global PrEP Network, a WHO-led forum designed…

Research, Normative Guidance/Policies, Testing

Event
4 October 2022

Acceptability of Injectable Pre-exposure Prophylaxis among People who Inject Drugs in Three Urban U.S. Settings

This article from BMC Infectious Diseases examines acceptability of injectable PrEP amongst people who inject drugs in the US.

Research

External Link